Exhibit 99.1 Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights · NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a program that has been granted Fast Track Designation by the FDA · NXP800 Investigator-sponsored clinical trial in cholangiocarcinoma initiated with the Mayo Clinic · NXP800 granted Orphan Drug Designation for the treatment of cholangiocarcinoma · NXP900 Phase 1a dose escalatio ...